These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35404549)

  • 1. Association of 340B contract pharmacy growth with county-level characteristics.
    Nikpay S; Gracia G; Geressu H; Conti R
    Am J Manag Care; 2022 Mar; 28(3):133-136. PubMed ID: 35404549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
    Clark BL; Hou J; Chou CH; Huang ES; Conti R
    Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.
    Watts E; McGlave C; Quinones N; Bruno JP; Nikpay S
    JAMA Health Forum; 2024 Oct; 5(10):e243360. PubMed ID: 39365605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
    Ruley M; Belcher M; Sayre H; Coustasse A
    Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges for Managed Care from 340B Contract Pharmacies.
    Fein AJ
    J Manag Care Spec Pharm; 2016 Mar; 22(3):197-203. PubMed ID: 27003548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 340B Contract pharmacy growth by pharmacy ownership: 2009-2022.
    McGlave C; Bruno JP; Watts E; Nikpay S
    Health Aff Sch; 2024 Jan; 2(1):qxad075. PubMed ID: 38756399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
    Lee CH; Chang J; McCombs J
    J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
    Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
    Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
    Conti RM; Bach PB
    Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
    Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
    JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between initiation of 340B participation and hospital safety-net engagement.
    Nikpay SS; Buntin MB; Conti RM
    Health Serv Res; 2020 Apr; 55(2):157-169. PubMed ID: 32187392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 340B Drug Pricing Program and hospital provision of uncompensated care.
    Desai SM; McWilliams JM
    Am J Manag Care; 2021 Oct; 27(10):432-437. PubMed ID: 34668672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
    Zeta LM
    Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a $4 generic drug program in a 340B pharmacy.
    Bright DR; Adams AJ; Akala FO; Lengel AJ; Martin SJ; Powers MF
    Am J Health Syst Pharm; 2010 Jun; 67(11):929-31. PubMed ID: 20484217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacy benefit manager reform within Medicaid Managed Care: The pursuit of a model that preserves the intent of the 340B program.
    Almeter PJ; Butler WR; Reynolds JW; Duckworth DL; Labuhn JA; Birdwhistell MD
    Am J Health Syst Pharm; 2022 Sep; 79(18):1607-1611. PubMed ID: 35020794
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.
    Levengood TW; Conti RM; Cahill S; Cole MB
    Milbank Q; 2024 Jun; 102(2):429-462. PubMed ID: 38282421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022.
    Nikpay S; McGlave CC; Bruno JP; Yang H; Watts E
    JAMA Health Forum; 2023 Aug; 4(8):e232139. PubMed ID: 37540525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.